Geron Corp. (GERN)

1.36
NASDAQ : Health Technology
Prev Close 1.44
Day Low/High 1.35 / 1.46
52 Wk Low/High 0.95 / 6.99
Avg Volume 1.58M
Exchange NASDAQ
Shares Outstanding 188.42M
Market Cap 271.33M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Geron Announces Conference Call To Discuss Financial Results For The 2010 Second Quarter

Geron Corporation (NASDAQ:GERN) will announce its financial results for the 2010 second quarter on Thursday, July 29, 2010, after the closing of the equity market.

Geron Initiates Randomized Phase 2 Clinical Trial Of Imetelstat In Non-Small Cell Lung Cancer

Geron Corporation (Nasdaq:GERN) today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following ...

Geron Provides Update On Telomerase Activation Program

Geron Corporation (Nasdaq:GERN) today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology (HKUST), are being fully consolidated into Geron.

Geron Corporation Q1 2010 Earnings Call Transcript

Geron Corporation Q1 2010 Earnings Call Transcript

Geron Presents Clinical Data On Its Telomerase Inhibitor Drug In Breast Cancer At ASCO

Geron Corporation (Nasdaq:GERN) today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company’s telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in...

Geron Appoints Hoyoung Huh And Robert Spiegel To Its Board Of Directors

Geron Corporation (Nasdaq: GERN) today announced the appointment of Hoyoung Huh, M.

Geron Announces Positive Data On Its Small Molecule Telomerase Activator In Model Of Idiopathic Pulmonary Fibrosis

Geron Corporation (Nasdaq: GERN) today announced positive data on its orally available small molecule telomerase activator, TAT153, in an animal model of idiopathic pulmonary fibrosis (IPF).

Geron To Present At The Rodman & Renshaw Annual Global Healthcare Conference

Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.

Geron Announces Positive Study Data On GRNCM1

Geron Corporation (Nasdaq:GERN) today reported positive preclinical study data showing that GRNCM1, Geron’s cardiomyocyte product derived from human embryonic stem cells (hESCs), does not cause cardiac ...

Geron Comments On Decision By U.S. PTO On WARF Patent

Geron Corporation (Nasdaq:GERN) announced today that the Board of Patent Appeals and Interferences of the U.

Geron Corporation Reports 2010 First Quarter Financial Results And Highlights

Geron Corporation (Nasdaq: GERN) today reported financial results for the three months ended March 31, 2010.

Geron Announces Conference Call To Discuss Financial Results For The 2010 First Quarter

Geron Corporation (Nasdaq:GERN) will announce its financial results for the 2010 first quarter on Wednesday, April 28, 2010, after the closing of the equity market.

Geron Gives Five Presentations On Telomerase Inhibitor Imetelstat At The AACR Annual Meeting

Geron Corporation (Nasdaq:GERN) today announced five presentations by Geron scientists and collaborators on the company’s telomerase inhibitor, imetelstat sodium (GRN163L), including the drug’s activity ...

Geron Appoints Thomas Hofstaetter To Board Of Directors And Announces Retirement Of Patrick Zenner

Geron Corporation (Nasdaq: GERN) today announced the appointment of Thomas Hofstaetter, Ph.

Corning Incorporated Introduces New Synthemax™ Synthetic Surface To Enhance And Support Stem Cell Growth

Corning Incorporated Introduces New Synthemax™ Synthetic Surface To Enhance And Support Stem Cell Growth

Corning Incorporated (NYSE:GLW) today introduced the Corning ® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells.

Presentations On Geron’s Telomerase Inhibitor At AACR Special Conference

Presentations On Geron’s Telomerase Inhibitor At AACR Special Conference

Geron Corporation (Nasdaq:GERN) today announced several presentations at the American Association for Cancer Research (AACR) Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort ...

Geron Announces Conference Call To Discuss Fourth Quarter And Annual 2009 Financial Results And Highlights

Geron Announces Conference Call To Discuss Fourth Quarter And Annual 2009 Financial Results And Highlights

Geron Corporation (Nasdaq:GERN) will announce its financial results for the 2009 fourth quarter and year end on Thursday, February 25, 2010, after the closing of the equity market.

Geron To Present At The BIO CEO & Investor Conference

Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.

Biotech Stock Mailbag Readers' Portfolio

Introducing the Biotech Stock Mailbag Readers' Portfolio, which highlights stocks picked by readers and regularly-updated analysis from columnist Adam Feuerstein.

Biotech Stock Mailbag: Year in Review

Biotech Stock Mailbag: Year in Review

Biotech stock watchdog Adam Feuerstein looks back at the best and worst of Mailbag 2009.

Early Volume Plays: QuadraMed, JA Solar

Early Volume Plays: QuadraMed, JA Solar

Several stocks trading under $10 were poised to move on above-average volume during Tuesday's session, including QuadraMed, Yongye and JA Solar.

Geron, StemCells: Late Day Volume Plays

Geron, StemCells: Late Day Volume Plays

Several stocks trading near $5 were moving on above-average volume during Wednesday's session.

Biotech Cos. Rise As Gov't OKs New Stem Cell Lines

Biotech Cos. Rise As Gov't OKs New Stem Cell Lines

Biotech companies soar as federal government names new stem cell lines for testing

Geron Hopes To Restart Stem-cell Study In 2010

Geron aims to restart human studies on stem-cell spinal-cord injury treatment in 3Q 2010

Geron Shares Rise On Merriman Analyst Upgrade

Geron Shares Rise On Merriman Analyst Upgrade

Geron shares rise on upgraded from Merriman Curhan Ford analyst, outlook for cancer program

Biotech Stock Mailbag: Oncothyreon

Biotech Stock Mailbag: Oncothyreon

Readers write in about Oncothyreon, Progenics, Chelsea Therapeutics and more.

Hemispherx CEO Spills Ampligen Beans to Stock Cheerleader: BioBuzz

'Important news' on Ampligen and FDA to be released by stock promoter Friday.

Targacept Unveils Depression Drug Data Next Week: BioBuzz

Targacept Unveils Depression Drug Data Next Week: BioBuzz

Stock price rises going into Oct. 15 presentation of TC-5214 data.

Hot Biotech Events for Next Week: BioBuzz

Investor conferences and phase III data on tap for post-Labor Day

Geron Says Some Animals Developed Cysts In Trial

Geron says a minority of rats and mice treated with its stem cell product had spinal cysts

TheStreet Quant Rating: D (Sell)